natgillin/translations-raw huggingface dataset:
- The other ingredients are: disodium hydrogen phosphate heptahydrate sodium dihydrogen phosphate dihydrate mannitol poloxamer 188 benzyl alcohol water for injections 
Drugi sastojci su: dinatrijev hidrogenfosfat heptahidrat natrijev dihidrogenfosfat dihidrat manitol poloksamer 188 benzilni alkohol voda za injekcije
Growth disturbance in chronic renal insufficiency A dose of 0.045 - 0.050 mg/kg body weight per day (1.4 mg/m2 body surface area per day) is recommended. 
Preporučuje se doza od 0,045 - 0,050 mg/kg tjelesne težine na dan (1,4 mg/m2 tjelesne površine na dan).
Omnitrope 10 mg/1.5 ml solution for injection EU/1/06/332/007 
Omnitrope 10 mg/1,5 ml otopina za injekciju EU/1/06/332/007
The treatment should be discontinued at renal transplantation. 
U slučaju transplantacije bubrega liječenje se mora prekinuti.
One cartridge contains 1.5 ml corresponding to 5 mg somatropin (15 IU). 
Jedan uložak sadrži 1,5 ml što odgovara količini od 5 mg somatropina (15 IU).
Omnitrope 1.3 mg/ml powder and solvent for solution for injection 
Omnitrope 1,3 mg/ml prašak i otapalo za otopinu za injekciju
- The other ingredients are: disodium hydrogen phosphate heptahydrate sodium dihydrogen phosphate dihydrate sodium chloride poloxamer 188 phenol water for injections 
Drugi sastojci su: dinatrijev hidrogenfosfat heptahidrat natrijev dihidrogenfosfat dihidrat natrijev klorid poloksamer 188 fenol voda za injekcije
Thyroid function 
Funkcija štitnjače
- The other ingredients are: disodium hydrogen phosphate heptahydrate sodium dihydrogen phosphate dihydrate glycine poloxamer 188 phenol water for injections 
Drugi sastojci su: dinatrijev hidrogenfosfat heptahidrat natrijev dihidrogenfosfat dihidrat glicin poloksamer 188 fenol voda za injekcije
INFORMATION IN BRAILLE Omnitrope 5 mg/1.5 ml 
16. PODACI NA BRAILLEOVOM PISMU Omnitrope 5 mg/1,5 ml
It should only be administered with SurePal 10, an injection device specifically developed for use with Omnitrope 10 mg/1.5 ml solution for injection. 
Smije se primjenjivati samo pomoću brizgalice SurePal 10, medicinskog proizvoda posebno izrađenog za primjenu Omnitrope 10 mg/1,5 ml otopine za injekciju.
Clinical trials in children with chronic renal insufficiency Table 3 
Klinička ispitivanja u djece s deficitom hormona rasta Tablica 1
Omnitrope 5 mg/ml powder and solvent for solution for injection 
Omnitrope 5 mg/ml prašak i otapalo za otopinu za injekciju
Metabolism and Nutrition Disorders 
Poremećaji metabolizma i prehrane dijabetes melitus tipa II
Omnitrope 1.3 mg/ml is supplied in a vial containing the active substance as a powder and the solvent filled in a vial for single use. 
6.6 Posebne mjere za zbrinjavanje i druga rukovanja lijekom Omnitrope 1,3 mg/ml se isporučuje u bočici koja sadrži djelatnu tvar u obliku praška i s otapalom u bočici za jednokratnu upotrebu.
Use only with Omnitrope Pen L. Read package leaflet before use. 
Koristiti samo uz SurePal 5. Prije uporabe pročitajte Uputu o lijeku.
It should only be administered with SurePal 15, an injection device specifically developed for use with Omnitrope 15 mg/1.5 ml solution for injection. 
Smije se primjenjivati samo pomoću brizgalice SurePal 15, medicinskog proizvoda posebno izrađenog za primjenu Omnitrope 15 mg/1,5 ml otopine za injekciju.
Omnitrope 15 mg/1.5 ml solution for injection EU/1/06/332/010 
Omnitrope 15 mg/1,5 ml otopina za injekciju EU/1/06/332/010
MARKETING AUTHORISATION NUMBERS EU/1/06/332/016 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/06/332/016
Omnitrope 5 mg/1.5 ml solution for injection EU/1/06/332/004 
Omnitrope 5 mg/1,5 ml otopina za injekciju EU/1/06/332/004
MARKETING AUTHORISATION NUMBERS EU/1/06/332/013 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/06/332/013
Omnitrope 5 mg/1.5 ml solution for injection EU/1/06/332/013 
Omnitrope 5 mg/1,5 ml otopina za injekciju EU/1/06/332/013
Powder in a vial (type I glass) with a stopper (fluor-resin laminated butyl rubber), a strip (aluminium) and a cap (violet polypropylene flip-off), and 1 ml of solvent in a vial (type I glass) with a stopper (fluor-resin laminated chlorobutyl elastomer), a strip (lacquered aluminium) and a cap (white polypropylene flip-off). 
(klorobutilni elastomer laminiran smolom fluora), dvoslojnica/strip (lakirani aluminij) i zatvarač (bijeli polipropilenski „flip-off“).
MARKETING AUTHORISATION NUMBERS EU/1/06/332/007 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/06/332/007
MARKETING AUTHORISATION NUMBERS EU/1/06/332/010 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/06/332/010
Prader-Willi syndrome, for improvement of growth and body composition in paediatric patients Generally a dose of 0.035 mg/kg body weight per day or 1.0 mg/m2 body surface area per day is recommended. 
Djeca s Prader-Willijevim sindromom: 0,035 mg/kg tjelesne težine na dan ili 1,0 mg/m2 površine tijela na dan.
Therefore caution should be exercised when Omnitrope is administered to breast-feeding women. 
Stoga je prilikom primjene Omnitropea kod dojilja potreban oprez.
NAME OF THE MEDICINAL PRODUCT Omnitrope 10 mg/1.5 ml solution for injection Somatropin 
Omnitrope 10 mg/1,5 ml otopina za injekciju somatropin
- SurePal, an injection device specifically developed for use with 
- SurePal, medicinski proizvod posebno izrađen za primjenu uz Omnitrope otopinu za injekciju (nije isporučeno u pakovanju;
It should only be administered with SurePal 5, an injection device specifically developed for use with Omnitrope 5 mg/1.5 ml solution for injection. 
Smije se primjenjivati samo pomoću brizgalice SurePal 5, medicinskog proizvoda posebno izrađenog za primjenu Omnitrope 5 mg/1,5 ml otopine za injekciju.
Paraesthesia 
Doziranje
NAME OF THE MEDICINAL PRODUCT Omnitrope 15 mg/1.5 ml solution for injection Somatropin 
Omnitrope 15 mg/1,5 ml otopina za injekciju somatropin
Measuring the dose of Omnitrope to be injected - Take the sterile, disposable syringe of appropriate size (e.g. 1 ml syringe) and injection needle (e.g. 0.25 mm x 8 mm). 
štrcaljku od 1 ml) i iglu za injekcije (npr. 0,25 mm x 8 mm).
MARKETING AUTHORISATION NUMBERS EU/1/06/332/004 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/06/332/004
If you get any side effects, talk to your doctor or pharmacist or nurse. 
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika ili medicinsku sestru.
The manufacturer's instructions with each pen must be followed for loading the cartridge, attaching the injection needle and for the administration. 
Prilikom umetanja uloška, pričvršćivanja injekcijske igle i primjene nužno je pridržavanje uputa proizvođača za svaku brizgalicu.
Fertility studies with Omnitrope have not been performed. 
Nisu provedena ispitivanja utjecaja Omnitropea na plodnost.
Each ml of solution contains 3.3 mg of somatropin (corresponding to 10 IU) One cartridge contains 5.0 mg (corresponding to 15 IU) of somatropin in 1.5 ml. 
Jedan uložak sadrži 10,0 mg (što odgovara vrijednosti od 30 IU) somatropina u 1,5 ml.
NAME OF THE MEDICINAL PRODUCT Omnitrope 5 mg/1.5 ml solution for injection Somatropin 
Omnitrope 5 mg/1,5 ml otopina za injekciju somatropin
Children with chronic renal (kidney) insufficiency 
Djeca s kroničnom insuficijencijom bubrega
MARKETING AUTHORISATION NUMBERS EU/1/06/332/002 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/06/332/002
Somatropin induces the retention of sodium, potassium and phosphorus. 
Somatropin potiče zadržavanje natrija,
To setup the pen dial the dose. 
Da biste podesili brizgalicu,
MARKETING AUTHORISATION NUMBER EU/1/06/332/001 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/06/332/001
Growth disturbance due to insufficient secretion of growth hormone in paediatric patients Generally a dose of 0.025 - 0.035 mg/kg body weight per day or 0.7 - 1.0 mg/m2 body surface area per day is recommended. 
Djeca s nedostatkom hormona rasta: 0,025-0,035 mg/kg tjelesne težine na dan ili 0,7-1,0 mg/m2 površine tijela na dan.
• If you have raised intracranial pressure (which causes symptoms, such as strong headache, visual disturbances or vomiting) you should inform your doctor about it. 
• povišen intrakranijalni tlak (koji uzrokuje simptome, kao što su jake glavobolje, poremećaji vida ili povraćanje) • bolovi u mišićima
Musculoskeletal , Connective Tissue and Bone Disorders 
Poremećaji mišićno koštanog sustava i vezivnog tkiva artralgija* mialgija*
NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Omnitrope 10 mg/1.5 ml Injection 
NAZIV LIJEKA I PUT PRIMJENE LIJEKA Omnitrope 10 mg/1,5 ml injekcija somatropin s.c.
8°C in the original package. 
utvrđena je stabilnost u primjeni do 24 sata pri 2 °C-8 °C u originalnom pakiranju.
Omnitrope 10 mg/1.5 ml solution for injection is for use in SurePal 10 only. 
Omnitrope 10 mg/1,5 ml otopine za injekciju postiže se poluvijek od 3 sata.
NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Omnitrope 15 mg/1.5 ml Injection 
NAZIV LIJEKA I PUT PRIMJENE LIJEKA Omnitrope 15 mg/1,5 ml injekcija somatropin s.c.
NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Omnitrope 5 mg/1.5 ml Injection 
NAZIV LIJEKA I PUT PRIMJENE LIJEKA Omnitrope 5 mg/1,5 ml injekcija somatropin s.c.
After the needle is in, remove the hand used to pinch the skin and use it to hold the syringe barrel. 
otpustite nabor kože između prstiju i tom rukom primite tijelo štrcaljke.
Whereas 
Kakvoća
Particularly the endpoint of main interest which is pain. 
Posebice krajnju točku od glavnog interesa, odnosno bol.
• The Committee considered the referral under Article 29(4) of Directive 2001/83/EC, 
• Odbor je razmotrio arbitražni postupak u skladu s člankom 29. stavkom 4. Direktive 2001/83/EZ.
The difference in median VAS score was 8 mm at day 3-4 and 4.6mm at day 7-8. 
Razlika u srednjoj vrijednosti VAS-a iznosila je 8 mm za 3. i 4. dan te 4,6 mm za 7. i 8. dan.
An effect was seen on the critical secondary endpoint of spontaneous pain visual analogue scale (VAS). 
Primijećen je učinak na kritičnu sekundarnu krajnju točku vizualne analogne ljestvice vizualne boli (VAS).
The product information remains as per the final version achieved during the Coordination group procedure as mentioned in Annex III of the CHMP opinion. 
Informacije o lijeku ostaju u skladu sa završnom verzijom donesenom tijekom postupka Koordinacijske grupe kako je navedeno u Prilogu III. mišljenja CHMP-a.
• The Committee considered the totality of the data submitted by the applicant in relation to the objections raised as a potential serious risk to public health. 
• Odbor je razmotrio ukupne podatke koje je podnositelj zahtjeva dostavio imajući u vidu primjedbe navedene kao potencijalne ozbiljne rizike po javno zdravlje.
The study was designed and powered to demonstrate superiority with a significant level of 5% one-sided, but the current requirement is now that a significance level of 2.5% one-sided, which the study could not reach. 
Ispitivanje je osmišljeno i pokrenuto da bi se pokazala nadmoćnost uz razinu značajnosti od 5 % za jednostrano ispitivanje, ali trenutačni zahtjev jest razina značajnosti od 2,5 % za jednostrano ispitivanje, a taj zahtjev ispitivanje nije ispunilo.
However, this study cannot be considered to provide confirmatory evidence on efficacy of Spraygel as the primary endpoint is not validated and statistical analysis does not meet regulatory requirements. 
No, ovo ispitivanje ne pruža nepobitne dokaze o učinkovitosti lijeka Spraygel jer primarna krajnja točka nije potvrđena, a statistička analiza ne ispunjava regulatorne zahtjeve.
The qualitative comparison is based on composition, degree of ionization and complete solubility of active substance. 
Usporedba kakvoće temelji se na sastavu, stupnju ionizacije i potpunoj topivosti djelatne tvari.
MIKA Pharma GmbH requested that the marketing authorisation for Diclofenac Sodium Spray Gel 4% granted by the UK in 2001, and subsequently granted by Austria, Estonia, Hungary, Ireland, Latvia, Lithuania and Slovenia, be also recognised in Germany, Italy and Spain as part of a “second wave” Mutual recognition procedure (MRP). 
Tvrtka MIKA Pharma GmbH zatražila je da odobrenje za puštanje lijeka u promet za Diclofenac Sodium Spray Gel 4 % koje je izdala Ujedinjena Kraljevina (UK) 2001., a nakon toga i Austrija, Estonija, Mađarska, Irska, Latvija, Litva i Slovenija, bude priznato i u Njemačkoj, Italiji i Španjolskoj u „drugom valu” postupka o uzajamnom prepoznavanju (MRP).
Clinical Pharmacology 
Klinička farmakologija
The application subject to this referral therefore concerns a repeat-use mutual recognition procedure (UK-H-0563-001-E-002) for Diclofenac sodium 4% cutaneous spray, solution (PL 18017/0006) with UK as RMS and which involves Italy, Spain, Germany as Concerned Member States. 
Predmet prijave ovog upućivanja stoga se odnosi na ponovljenu upotrebu postupka uzajamnog prepoznavanja (UK-H-0563-001-E-002) za lijek Diclofenac sodium 4% za kožnu primjenu (PL 18017/0006), pri čemu je UK referentna država članica, a postupak uključuje Italiju, Španjolsku i Njemačku kao predmetne države članice.
However, the systemic exposure is low enough that the adverse event profile seen with oral or other systemically administered NSAIDs is not problematic. 
No, sustavna je izloženost dovoljno niska da profil nuspojava koji je primijećen u NSAID-ova za oralnu ili drugu sustavnu primjenu nije problematičan.
• The Committee was of the view that the totality of data submitted justified the efficacy of the applied medicinal product as well as the bridging to the literature, in particular to existing data on topical diclofenac formulations including Voltarol Emulgel formulations. 
• Odbor smatra da svi podneseni podatci opravdavaju učinkovitost primijenjenog lijeka, kao i upućivanje na literaturu, posebno u pogledu formulacija diklofenaka za lokalnu primjenu, uključujući formulacije Voltarol Emulgel.
The plasma and tissue pharmacokinetic (PK) data of SprayGel in healthy volunteers, and patients with acute inflammation, are compared to those of Voltaren Sodium Gel and Voltaren Emulgel. 
Farmakokinetički podatci za plazmu i tkivo za SprayGel u zdravih dobrovoljaca i bolesnika s akutnom upalom uspoređeni su s podatcima bolesnika koji su primali Voltaren Sodium Gel i Voltaren Emulgel.
Numerically, the exposure of Spraygel is lower than Emulgel and its impact on efficacy cannot be ascertained accurately. 
Brojčana izloženost lijeka Spraygel niža je od izloženosti lijeka Emulgel te se njegov učinak na učinkovitost ne može sigurno procijeniti.
The applicant has also reviewed the available published clinical trial literature on topical diclofenac which includes a study on effects of Emulgel on Joint Pain (Predel 2012), study on DHEP (Diclofenac hydroxyethylpyrrolidine plaster), Heparin plaster or placebo plaster (Constantino C et al. 2011) and an uncontrolled study on DHEP gel. 
Podnositelj prijave pregledao je i dostupnu objavljenu literaturu o kliničkim ispitivanjima o diklofenaku za lokalnu primjenu, uključujući ispitivanje o učincima lijeka Emulgel na bol u zglobovima (Predel 2012.), ispitivanje o DHEP-u (zavoj diklofenaka hidroksietilpirolidin), heparinskom zavoju ili placebo zavoju (Constantino C. i dr. 2011.) i nekontrolirano ispitivanje o gelu DHEP.
All these studies provide evidence on modest efficacy for authorised topical diclofenac formulations of which the most robust is study Predel 2012 with Emulgel,. 
Sva ta ispitivanja pružaju dokaze o skromnoj učinkovitosti odobrenih formulacija diklofenaka za lokalnu primjenu, pri čemu najopsežnije dokaze ima ispitivanje lijeka Emulgel (Predel, 2012.).
The applicant included a review of the Predel 2013 study [previously pre-publication known as Study 9702SUV] on the efficacy of Spraygel in acute ankle injury. 
Predel iz 2013. (prethodno izdanje poznato je kao ispitivanje 9702SUV) o učinkovitosti lijeka Spraygel u pogledu akutne ozljede zgloba.
Although the strength of the proposed cutaneous spray is 4% as compared to the Emulgel which is 1% or 2%, this difference in the cutaneous spray was designed to deliver a similar amount of diclofenac to local tissues as the Emulgel. 
Iako jačina predloženog spreja za kožu iznosi 4 % u usporedbi s lijekom Emulgel jačine 1 % ili 2 %, ta razlika u spreju za kožu omogućuje primjenu slične količine diklofenaka na lokalna tkiva kao i kod lijeka Emulgel.
The only intra-study comparative data that is available is from study Martin et al. 1997 which indicated that the systemic absorption is comparable for Spraygel and Emulgel, but a conclusion on equivalence - and clinical relevance of systemic absorption - cannot be drawn. 
Jedini komparativni podatci dostupni su iz ispitivanja koje su proveli Martin i dr. iz 1997. u kojem je pokazano da se sustavna apsorpcija lijekova Spraygel i Emulgel može usporediti, ali nije moguće donijeti zaključak o ekvivalentnosti ni o kliničkoj važnosti sustavne apsorpcije.
The CHMP agreed that topical NSAIDs, including Diclofenac Sodium Spray Gel 4 %, have a proven safety record over many more than 10 years, which is supported by their low systemic bioavailability compared to e.g. oral pharmaceutical forms. 
CHMP se složio s tvrdnjom da NSAID-ovi, uključujući Diclofenac Sodium Spray Gel 4 % imaju dokazani sigurnosni profil već više od 10 godina, a potkrepljuje ga niska sustavna biodostupnost u usporedbi s npr. oralnim farmaceutskim oblicima.
The applicant's submissions as part of the referral procedure incorporates literature data and discussions on Quality, Clinical Pharmacology, Clinical Efficacy and Clinical Safety aspects. 
Podatci koje je podnio podnositelj prijave u okviru postupka upućivanja obuhvaćaju rasprave iz literature o kakvoći, kliničkoj farmakologiji, kliničkoj učinkovitosti i kliničkoj sigurnosti.
Most of the data are cross-study comparisons which are affected by different doses and methods and so no robust conclusions can be drawn from these cross-study comparisons. 
Većina podataka uglavnom su usporedbe iz više ispitivanja te se odnose na različite doze i načine primjene tako da iz njih nije moguće izvući zaključke utemeljene na više ispitivanja.
However, the study can be considered supportive of efficacy to infer that Spraygel has beneficial activity in the context of this bibliographic application. 
Međutim, ovim se ispitivanjem potkrjepljuju podatci o učinkovitosti lijeka Spraygel i njegovom blagotvornom djelovanju u kontekstu ove bibliografske prijave.
The Committee considered the available data submitted in support of the use of Diclofenac Sodium Spray Gel 4 % Cutaneous Spray, Solution and associated names , which included a comparison of quality aspects in relation to authorised topical diclofenac products, and literature covering pharmacokinetic (local and systemic) as well as efficacy and safety data. 
Odbor je u obzir uzeo dostupne podatke dostavljene u izvješću o uporabi lijeka Diclofenac Sodium Spray Gel 4 % za kožnu primjenu i pridruženih naziva, uključujući usporedbu aspekata kvalitete u odnosu na odobrene lijekove s diklofenakom za lokalnu primjenu, kao i literaturu s farmakokinetičkim (lokalnim i sustavim) podacima te podacima o sigurnosti i učinkovitosti.
Further as the systemic and topical exposure data of Emulgel is available for comparison to Spraygel, the Marketing Authorisation Holder bridged the efficacy of Emulgel to Spraygel based on a cross-study comparison of the efficacy endpoints, which are however confounded by differences in study methods and populations. 
Budući da su podatci o sustavnoj i lokalnoj izloženosti lijeka Emulgel dostupni za usporedbu s podatcima za Spraygel, nositelj odobrenja za stavljanje lijeka u promet povezuje učinkovitost lijekova Emulgel i Spraygel na temelju usporedbe iz više ispitivanja krajnjih točki učinkovitosti, no one nisu potpuno jasne zbog različitih metoda i populacija korištenih u ispitivanju.
The original application in 2000 under Article 4.8 (a) (II) of Directive 65/65/EEC - bibliographic for new pharmaceutical form and strength, was supported with published literature on efficacy of topical diclofenac as well as data from pharmacokinetics and a clinical study (9702 SUV) of the proposed 4% cutaneous spray formulation. 
Direktive 65/65/EEZ - bibliografski podatci za novi farmaceutski oblik i jačinu - potkrijepljena je objavljenom literaturom o učinkovitosti diklofenaka za lokalnu primjenu, kao i podatcima iz farmakološkog i kliničkog ispitivanja (9702 SUV) predložene formulacije spreja za kožu jačine 4 %.
Nevertheless, it is consistently seen across studies that measurable levels of diclofenac have been reported after application of the spraygel both in systemic exposure and topical exposure (subcutaneous tissue and muscle tissue) at the site of action. 
Međutim, u ispitivanjima je dosljedno prikazano da su prijavljene mjerljive razine diklofenaka nakon primjene gela u spreju, i kod sustavne i lokalne izloženosti (subkutano tkivo i mišićno tkivo) na mjestu primjene.
The defined primary endpoint response, expressed as a decrease in swelling of at least 50% during 10 days of treatment for the ‘Full Analysis Set' (FAS), was reached in 87/97 patients treated with diclofenac spray gel (89.7%) compared to 
Definirana primarna krajnja točka odgovora, izražena kao smanjenje oteknuća za najmanje 50 % tijekom 10 dana liječenja za „potpuni skup za analizu” (FAS), dosegnuta je u 87/97 bolesnika koji su liječeni gelom u spreju s diklofenakom (89,7 %) u usporedbi sa 74/94 bolesnika liječenih placebom (78,7 %); p = 0,0292 (jednostrano) i p = 0,0467 (dvostrano).
Day 60 of the CMDh procedure was on 29 March 2018, and since two Member States raised concerns regarding potential serious risk to public health (PSRPH) related to lack of efficacy for the specific 4% spraygel product and inadequate bridging to literature, in particular with other topical diclofenac formulations (including Voltarol Emulgel) for which it was acknowledged that there was adequate evidence of efficacy and safety, the Reference Member State (UK) triggered on 5 April 2018 a referral under Article 29(4) of Directive 2001/83/EC, requesting the CHMP to assess the impact of the objections raised that constitute a potential serious risk to public health. 
Budući da su dvije države članice izrazile zabrinutost u pogledu mogućeg ozbiljneog rizika za javno zdravlje u vezi s manjkom učinkovitosti specifičnog lijeka jačine 4 %u obliku gela u spreju i manjkavim upućivanjem na literaturu, posebno u odnosu na druge formulacije diklofenaka za lokalnu primjenu (uključujući Voltarol Emulgel) za koje je poznato da ne postoje odgovarajući dokazi učinkovitosti i sigurnosti, referentna država članica (UK) 5. travnja 2018. pokrenula je postupak upućivanja na temelju članka 29. stavka 4.
The Committee, as a consequence, considers that the benefit-risk balance of Diclofenac Sodium Spray Gel 4 % Cutaneous Spray, Solution and associated names is favourable and therefore recommends the granting of the marketing authorisation(s) for the medicinal products referred to in Annex I of the CHMP opinion. 
Odbor, posljedično, smatra da je omjer koristi i rizika spreja za kožu Diclofenac Sodium Spray Gel 4 % za kožnu primjenu i pridruženih naziva povoljan te stoga preporučuje izdavanje odobrenja za stavljanje u promet lijeka navedenog u Prilogu I. mišljenja CHMP-a.
Therefore the CHMP agreed by majority, that the benefit-risk balance of Diclofenac Sodium Spray Gel 4 % is favourable. 
Stoga je CHMP većinski odlučio da je omjer koristi i rizika za Diclofenac Sodium Spray Gel 4 % povoljan.
Overall summary of the scientific evaluation by the CHMP In summary, when taken together the totality of scientific evidence supports that Diclofenac Sodium Spray Gel 4 % has an acceptable safety and efficacy profile. 
Uglavnom, ukupni znanstveni dokazi govore u prilog tome da lijek Diclofenac Sodium Spray Gel 4 % ima prihvatljivi sigurnosni i djelotvorni profil.